Bosnar M H, Pavelić K, Hrasćan R, Zeljko Z, Krhen I, Marekoyic Z, Krizanac S, Pavelíc J
Division of Molecular Medicine, Ruder Bosković Institute, Zagreb, Croatia.
J Cancer Res Clin Oncol. 1997;123(9):485-8. doi: 10.1007/BF01192202.
This study evaluates the potential contribution of the nm23-H1 gene to malignant transformation in patients with renal cell carcinoma. Using specific oligonucleotide primers for the nm23-H1 microsatellite repetitive sequence, gene instability was followed by polymerase chain reaction/loss of heterozygosity assay on 54 tumor specimens and the corresponding normal tissue samples. We also determined, immunohistochemically, the relative concentration and localization of the nm23-H1 protein product. From 77.7% informative cases, DNA from 6 tumors exhibited loss of heterozygosity, regardless of the tumor stage (TNM). Out of 39 samples analyzed, 30 were negative for Nm23-H1 protein, while the others were only slightly positive. No correlation with tumor stage was found. Normal renal tissue was also negative for this protein. Our results provide the evidence for loss of heterozygosity, followed by means of microsatellite tandem-repeat polymorphism, at the nm23-H1 locus in renal cell carcinoma. However, since no correlation was found between the tumor stage or metastatic potential on the one hand, and allelic loss and specific protein expression on the other, it seems that nm23-H1 does not play a key role in the invasiveness of this tumor type.
本研究评估nm23-H1基因在肾细胞癌患者恶性转化中的潜在作用。使用针对nm23-H1微卫星重复序列的特异性寡核苷酸引物,通过聚合酶链反应/杂合性缺失分析,对54个肿瘤标本及相应的正常组织样本进行基因不稳定检测。我们还通过免疫组织化学方法测定了nm23-H1蛋白产物的相对浓度和定位。在77.7%的信息性病例中,6个肿瘤的DNA显示杂合性缺失,与肿瘤分期(TNM)无关。在分析的39个样本中,30个样本的Nm23-H1蛋白呈阴性,其余样本仅呈弱阳性。未发现与肿瘤分期相关。正常肾组织中该蛋白也呈阴性。我们的结果为肾细胞癌中nm23-H1基因座通过微卫星串联重复多态性导致杂合性缺失提供了证据。然而,由于一方面肿瘤分期或转移潜能与另一方面的等位基因缺失和特定蛋白表达之间未发现相关性,似乎nm23-H1在这种肿瘤类型的侵袭性中不发挥关键作用。